Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody
✍ Scribed by Julian A. Kim; Herbert S. Bresler; Edward W. Martin Jr.; Wayne Aldrich; Marilyn Heffelfinger; Pierre L. Triozzi
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 605 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
The authors showed previously that radiolabeled monoclonal antibody (MoAb) and a hand-held, gamma-detecting probe can be used to localize tumor-reactive lymph nodes in vivo. The authors examined the feasibility, safety, and biologic effects of cellular immunotherapy using autologous cells expanded from these lymph nodes in patients with metastatic colorectal carcinoma.
METHODS.
Tumor-reactive lymph nodes containing radiolabeled MoAb were localized and excised from 32 patients with metastatic, unresectable colorectal carcinoma at laparotomy. Lymph nodes were dissociated, and cells were cultured ex vivo for 10 -14 days. Patients received a single infusion of autologous, expanded cells with no systemic interleukin (IL)-2.